Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Why Did The Sirtex Medical Limited Share Price Explode Today?

The Sirtex Medical Limited (ASX:SRX) share price exploded higher on Wednesday following a takeover offer from Varian Medical Systems, Inc (NYSE:VAR).

The Sirtex Medical Limited (ASX: SRX) share price exploded higher on Wednesday following a takeover offer from California’s Varian Medical Systems, Inc (NYSE: VAR).

Sirtex Medical shares entered a trading halt on Tuesday morning before it filed a trading update after the ASX closed.

The board of Sirtex Medical said it recommends shareholders approve the acquisition by Varian Medical, which values Sirtex at $28 per share or $1.6 billion in total.

Commenting on the takeover (“scheme”) Dr John Eady, Sirtex Medical’s interim Chairman, said, “In recommending the Scheme, we have considered the future potential prospects and the risks associated with an investment in Sirtex.”

“Whilst we remain confident that the Company would continue to have a successful stand-alone future, we believe that the material premium provided by Varian and the certainty of all cash consideration is an attractive outcome for shareholders.”

The cash offer of $28 is 49% higher than Sirtex Medical’s share price of $18.83 earlier in the week, and a steep 77% premium to the three-month average share price.

However, the takeover offer may be bittersweet for some long-term Sirtex Medical shareholders who watched the company’s shares fall from around $40 in 2015 to less than $12 in mid-2017.

For the $15 billion Varian Medical, a $1.6 billion deal for Sirtex Medical adds to its existing efforts in the fight against cancer.

“Sirtex is a highly complementary strategic fit with our existing solutions for the treatment of cancer,” Varian CEO Dow Wilson said. “We are excited by the opportunity to expand Sirtex’s business and continue to provide physicians and patients around the world with smart, efficient, and high-quality care.”

Sirtex said it received “a number of unsolicited, non-binding acquisition proposals” late in 2017 following the huge fallout in its share price, doubt over the efficacy of its products, legal headaches and managerial uncertainty.

An official Varian Medical and Sirtex Medical tie-up is subject to an independent expert report, regulatory and court approval, and ‘no material changes’.

Shareholders are likely to receive their scheme booklets in early-to-mid April, with the implementation of the deal expected in late May.

Sirtex Medical shares were trading 46% higher at $27.50 on Wednesday.

Want To Join An Investor’s Club Newsletter?

You can join Rask’s FREE investor’s club newsletter today for all of the latest analysis and education on investing. Join today – it doesn’t cost a thing.

Keep Reading

 

Disclaimer: This article contains general information only. It is no substitute for licenced financial advice and should not be relied upon. By using our website you agree to our Disclaimer & Terms of Use and Privacy Policy.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

5%+ in passive income

Owen Rask’s investing report available

With bond ETFs like ASX:IAF and the S&P 500 riding high, now could be one of the best times to start earning passive income from a portfolio of shares and ETFs.

In this free analyst report, our Chief Investment Officer, Owen Rask, names 10 ASX stocks and ETFs to watch.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Skip to content